Table 1

Overview of aetiology, infection foci, and treatment regiment for the bacteraemia episodes presented.

EpisodeInitial identificationFinal identificationInfection focusTreatment
(I) 5 July 06S aureus in 6/6 bottlesS aureusMitral valve endocarditisCefuroxime 1.5 g BID, rifampicin 300 mg TID and fucidic acid 500 mg TID for 6 weeks
(II) 31 Aug 06CoNS in 6/9 bottlesS aureus (CoNS contaminant in one of the bottles)Unknown*Dicloxacillin 2 g TID, vancomycin 1 g QD and fucidic acid 500 mg TID for 3 weeks, afterwards vancomycin 1 g QD for further 3 weeks.
(III) 2 Nov 06S aureus and CoNS in 9/9 bottlesS aureus (CoNS contaminant in one of the bottles)Unknown*Cefuroxime 1.5 g BID, vancomycin 1 g QD and fucidic acid 500 mg TID for 2 weeks and, subsequently, rifampicin 600 mg BID and fucidic acid 500 mg TID for 7 weeks
(IV) 9 Feb 07S. aureus and CoNS in 9/9 bottlesS aureusUnknown*Cefuroxime 1.5 g BID and vancomycin 1 g QD for 2 weeks
(V) 14 March 07S aureus in 3/3 bottlesS aureusUnknown*Cefuroxime 3 g QD and vancomycin 1 g QD for 4 weeks followed by continuous cefuroxime axetil 1 g BID prophylactic treatments
  • *Infection focus in episodes II, III, IV and IV were assumed to be a pacemaker.

  • BID, twice daily; CoNS, coagulase negative Staphylococcus; QD, four times daily; TID, three times daily.